Abstract:Numerous anti-inflammatory agents and corresponding therapeutic strategies have been explored for treating inflammation-related atherosclerosis, which has struggled with compromised antiatherosclerotic efficacy due to the complex pathogenesis. The senescent endothelial cells participate fundamentally at all stages in atherosclerosis, providing the basis for developing senotherapies to blunt the deleterious effects of senescent cells. In this work, a mesoporous palladium-boron-phosphorus ternary nanozyme with intrinsic superoxide dismutase/catalase-mimicking properties is rationally engineered to co-load H2 (an anti-inflammatory agent) within nanozyme's crystal lattice and 4,4 '-dimethoxychalcone (DIM, an anti-senescence agent) within mesopores, which elicits strong anti-inflammatory effect in pro-inflammatory macrophages by elimination of reactive oxygen species (ROS), H2 anti-inflammation and promotion of cholesterol efflux, while simultaneously exerts anti-senescence capacity in endothelial cells by protection of DNA from ROS damage and degradation of the cellular senescent components via autophagy activation. Both in vitro and in vivo experimental results verify the synergy between nanozyme-based anti-inflammatory therapy and autophagy activation, demonstrating that such a precise regulation of vascular senescence is applicable to augment antiatherosclerotic efficiency, which provides the nanomedicine-enabled and senotherapy-based paradigm for atherosclerosis management. A mesoporous palladium-boron-phosphorus ternary nanozyme with superoxide dismutase/catalase-mimicking abilities is developed to co-load H2 (an anti-inflammatory agent) within nanozyme's crystal lattice and 4,4 '-dimethoxychalcone (DIM, an anti-senescence agent) within mesopores, which elicits strong anti-inflammatory effect in pro-inflammatory macrophages, while simultaneously exerts anti-senescence capacity in endothelial cells, finally achieving desirable therapeutic effect for treatment of atherosclerosis. image

Engineering Hierarchical Recognition-Mediated Senolytics for Reliable Regulation of Cellular Senescence and Anti-Atherosclerosis Therapy

Targeted clearance of senescent cells using an antibody-drug conjugate against a specific membrane marker

Mesoporous Ternary Nanozymes with Anti‐Senescence and Anti‐Inflammation Activities for Atherosclerosis Management

Combating Atherosclerosis with Chirality/Phase Dual‐Engineered Nanozyme Featuring Microenvironment‐Programmed Senolytic and Senomorphic Actions

Targeted Regulation of Senescence-Associated Secretory Phenotype with an Aptamer-Conjugated Activatable Senomorphic

Targeting Cellular Senescence in Aging and Age-Related Diseases: Challenges, Considerations, and the Emerging Role of Senolytic and Senomorphic Therapies

Integrated Cascade Nanozymes with Antisenescence Activities for Atherosclerosis Therapy

Spatially Confined Intervention of Cellular Senescence by a Lysosomal Metabolism Targeting Molecular Prodrug for Broad-Spectrum Senotherapy

Senolytic Therapy Enabled by Senescent Cell‐Sensitive Biomimetic Melanin Nano‐senolytics

Photoactivatable senolysis with single-cell resolution delays aging

Targeting senescent cells in atherosclerosis: Pathways to novel therapies

Targeting cellular senescence with senotherapeutics: senolytics and senomorphics

Targeting senescent cells for vascular aging and related diseases

A senolytic strategy integrating multiple technologies delays aging

Antagonizing the irreversible thrombomodulin-initiated proteolytic signaling alleviates age-related liver fibrosis via senescent cell killing

Targeting vascular senescence in cardiovascular disease with aging

Activatable and Self-Monitoring Hydrogen Sulfide-Based Molecular Senomorphics for Visualized Regulation of Cellular Senescence

Discovery and Repurposing of Multi-Target Senolytics through Structure-Based Virtual Screening

Application potential of senolytics in clinical treatment

Advances in Nanotherapy for Targeting Senescent Cells

Understanding the Intricacies of Cellular Senescence in Atherosclerosis: Mechanisms and Therapeutic Implications